TD Cowen maintains Krystal Biotech at Buy, lowers price target to $380 from $403
TD Cowen kept its Buy rating on Krystal Biotech but reduced its price target to $380 from $403, a 5.7% decrease. The new target suggests a 28.4% upside from the Nov 2 close of $295.90, according to the firm.
How this was made
The 30-second read
Why it matters
A lower price target can influence positioning and expectations, but the unchanged Buy rating suggests the core thesis remains supportive.
Market read
Valuation expectations for KRYS are adjusted downward by TD Cowen, with limited immediate catalyst beyond the PT change.
What to watch
Without the underlying rationale for the PT change, traders may overreact to the number versus the unchanged recommendation.
Background
The piece is an analyst note summary from TD Cowen, not a company disclosure.
Ticker impact
TD Cowen maintained Krystal Biotech at Buy but cut its price target to $380 from $403, signaling a valuation reset despite the unchanged rating.
Likely mild downside bias as traders price in the lower target, while the unchanged Buy rating limits downside follow-through.
The article provides a specific, same-day analyst price-target cut with no new operational or clinical catalyst described.
Market effects
Limited read-through to biotech peers because this is a single-name valuation adjustment without new trial or regulatory data.
No clear regional spillover implied.
No global market linkage indicated.
Counterpoint
The unchanged Buy rating may matter more than the PT cut, suggesting the downgrade is incremental rather than a thesis break.
Key entities
- companyKrystal Biotech
Subject of the analyst action: maintained Buy, lowered price target to $380 from $403.
